SCHEMBL6202986

SCHEMBL6202986

Fc1ccc(-c2oc3ncnc(Cl)c3c2-c2ccc(Br)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
HPGD P15428 3/20 0.45
KDM4E B2RXH2 2/20 0.45
UBE2N P61088 2/20 0.45
TSHR P16473 2/20 0.45
HSD17B10 Q99714 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
MAPK1 P28482 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TNK2 Q07912 1/20 0.44
TEK Q02763 4/20 0.42
KDR P35968 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 1/20 0.40
AURKA O14965 4/20 0.39
MERTK Q12866 1/20 0.38
CHEK1 O14757 4/20 0.38
MAP2K1 Q02750 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1790077 1.00 ALDH1A1 (0.45) ALDH1A1HPGDKDM4EUBE2NTSHR
SCHEMBL1787179 0.88 TNK2 (0.58) ALDH1A1HPGDKDM4EUBE2NTSHR
SCHEMBL6848486 0.88 TNK2 (0.58) ALDH1A1HPGDKDM4EUBE2NTSHR
SCHEMBL20492595 0.83 SMN1; SMN2 (0.43) ALDH1A1HPGDKDM4EUBE2NTSHR
SCHEMBL6200319 0.83 ALDH1A1 (0.41) ALDH1A1HPGDKDM4EUBE2NTSHR
SCHEMBL735560 0.79 TNK2 (0.68) ALDH1A1HPGDKDM4EUBE2NTSHR
SCHEMBL22320612 0.77 ALDH1A1 (0.41) ALDH1A1HPGDKDM4EUBE2NTSHR
SCHEMBL22320704 0.77 ALDH1A1 (0.41) ALDH1A1HPGDKDM4EUBE2NTSHR
SCHEMBL6202459 0.77 ALDH1A1 (0.53) ALDH1A1HPGDKDM4EUBE2NTSHR
SCHEMBL1786166 0.76 TEK (0.71) ALDH1A1HPGDKDM4EUBE2NTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1425283-B1 NOVEL 4-AMINOFUROPYRIMIDINES AND THE USE THEREOF BAYER HEALTHCARE AG (DE) 2005-03-16 EP disclosed
US-20040259888-A1 Novel 4-aminofuropyrimidines and the use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259888-A1 Novel 4-aminofuropyrimidines and the use thereof DPYD, TPMT, TYMP ALDH1A1 176/4885HPGD 389/4885KDM4E 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.